Buy Lopimune Tablets Online Best Price
Lopinavir 200 mg + Ritonavir 50 mg
Lopimune Tablet is a combination of two antiretrovirals. It is prescribed to treat HIV (human immunodeficiency virus) infection. It boosts up the immunity to fight against HIV to manage or treat AIDS (acquired immunodeficiency syndrome).
Lopimune Tablet restricts the growth of HIV in the body and reduces the risk of getting HIV-related complications to improve the lifespan of an individual. The medicine should be taken with food for better efficacy. Taking these medicines regularly at the same time increases their effectiveness. A dose of this medicine should not be missed as it can affect your recovery. It is important to complete the full course of the treatment until your doctor advises you to stop it.
The most common side effects of this medicine are diarrhea, nausea, vomiting, and increased blood fat levels (hypertriglyceridemia and hypercholesterolemia). These side effects are generally temporary, but if they persist or become serious inform your doctor. Drinking plenty of fluid can help you to cope up with these side effects, so stay hydrated. In addition to that, avoid alcohol consumption as it may increase the intensity of the side effects.
Before starting with the treatment, you should consult your doctor if you are pregnant or breastfeeding, or have any health condition. Your doctor may suggest regular laboratory tests to check your blood counts, kidney and liver functions, and other health conditions. If you are HIV positive, you should not breastfeed or share personal belongings like razors or toothbrushes. Consult your doctor to know about safe sex methods in order to prevent transmission of HIV during intercourse.
USES OF LOPIMUNE TABLET
SIDE EFFECTS OF LOPIMUNE TABLET
Increased liver enzymes
Increased blood lipid level
Peripheral neuropathy (tingling and numbness of feet and hand)
HOW TO USE LOPIMUNE TABLET
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Lopimune Tablet is to be taken with food.
HOW LOPIMUNE TABLET WORKS
Lopimune Tablet is a combination of two anti-HIV medicines: Ritonavir and Lopinavir. They work by interfering with an enzyme (protease), which is required by HIV-infected cells to make new viruses. This stops the production of new viruses.
Caution is advised when consuming alcohol with Lopimune Tablet. Please consult your doctor.
CONSULT YOUR DOCTOR
Lopimune Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
SAFE IF PRESCRIBED
Lopimune Tablet is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
CONSULT YOUR DOCTOR
It is not known whether Lopimune Tablet alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
SAFE IF PRESCRIBED
Lopimune Tablet is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Lopimune Tablet may not be needed in these patients. Please consult your doctor.
Lopimune Tablet should be used with caution in patients with liver disease. Dose adjustment of Lopimune Tablet may be needed. Please consult your doctor.
Each film-coated tablet contains
Oral, Film coated tablets
LOPIMUNE is a co-formulation of lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV-1 protease.
Co-formulated as Lopinavir/ritonavir, it inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.
The effect of Lopinavir/ritonavir on QTcF interval was evaluated in a placebo and active (moxifloxacin 400 mg once daily) controlled crossover study in 39 healthy adults. The maximum mean time-matched (95% upper confidence bound) differences in QTcF interval from placebo after baseline-correction were 5.3 (8.1) and 15.2 (18.0) mseconds (msec) for 400/100 mg twice daily and supratherapeutic 800/200 mg twice daily lopinavir/ritonavir, respectively. lopinavir/ritonavir 800/200 mg twice daily resulted in a Day 3 mean Cmax approximately 2-fold higher than the mean Cmax observed with the approved once daily and twice daily lopinavir/ritonavir doses at steady state. The maximum mean (95% upper confidence bound) difference from placebo in the PR interval after baseline-correction were 24.9 (21.5, 28.3) and 31.9 (28.5, 35.3) msec for 400/100 mg twice daily and supratherapeutic 800/200 mg twice daily lopinavir/ritonavir, respectively (see WARNINGS AND PRECAUTIONS).
The pharmacokinetic properties of lopinavir are summarized in Table 1. The steady-state pharmacokinetic parameters of lopinavir are summarized in Table 2. Under fed conditions, lopinavir concentrations were similar following administration of lopinavir/ritonavir tablets to capsules with less pharmacokinetic variability.
Table 1: Pharmacokinetic properties of lopinavir
4.4 ± 0.8
Effect of meal (relative to fasting)
↑ 19%b↑ 130%b
% Bound to human plasma proteins
Major route of elimination
6.9 ± 2.2
% of dose excreted in urine
10.4 ± 2.3
% of dose excreted in feces
82.6 ± 2.5
a. Lopinavir/ritonavir tablet
b. Changes in AUC values
Table 2. Steady-State pharmacokinetic parameters of lopinavir, mean ± SD
9.8 ± 3.7
11.8 ± 3.7